CCND1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 5 bp deletion in exon 1.
Images
Key facts
- Cell type
HeLa
- Species or organism
Human
- Tissue
Cervix
- Knockout validation
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, Homozygous: 5 bp deletion in exon 1.
Alternative names
AI327039, B cell CLL/lymphoma 1, B cell leukemia 1, B-cell lymphoma 1 protein, BCL-1, BCL-1 oncogene, CCND1/FSTL3 fusion gene, CCND1/FSTL3 fusion gene, included, CCND1/IGHG1 fusion gene, CCND1/IGHG1 fusion gene, included, CCND1/IGLC1 fusion gene, CCND1/IGLC1 fusion gene, included, CCND1/PTH fusion gene, CCND1/PTH fusion gene, included, CCND1_HUMAN, CD1, Cyl 1, D11S287E, G1/S-specific cyclin-D1, PRAD1, PRAD1 oncogene, Parathyroid adenomatosis 1, U21B31
What's included?
Recommended products
CCND1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 5 bp deletion in exon 1.
Alternative names
AI327039, B cell CLL/lymphoma 1, B cell leukemia 1, B-cell lymphoma 1 protein, BCL-1, BCL-1 oncogene, CCND1/FSTL3 fusion gene, CCND1/FSTL3 fusion gene, included, CCND1/IGHG1 fusion gene, CCND1/IGHG1 fusion gene, included, CCND1/IGLC1 fusion gene, CCND1/IGLC1 fusion gene, included, CCND1/PTH fusion gene, CCND1/PTH fusion gene, included, CCND1_HUMAN, CD1, Cyl 1, D11S287E, G1/S-specific cyclin-D1, PRAD1, PRAD1 oncogene, Parathyroid adenomatosis 1, U21B31
Key facts
- Cell type
HeLa
- Species or organism
Human
- Tissue
Cervix
- Knockout validation
Sanger Sequencing, Western blot
- Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 5 bp deletion in exon 1.
- Disease
Adenocarcinoma
- Concentration
Properties
- Gene name
CCND1
- Gene editing type
Knockout
- Gene editing method
CRISPR technology
- Knockout validation
Sanger Sequencing, Western blot
- Zygosity
Homozygous
Quality control
- STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
EU: 2 US: 2
- Adherent/suspension
Adherent
- Gender
Female
Storage
- Shipped at conditions
Ambient - Can Ship with Ice
- Appropriate long-term storage conditions
-20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human CCND1 (Cyclin D1) knockout HeLa cell lysate (ab263808)
Lane 1: Wild-type HeLa cell lysate (20μg)
Lane 2: CCND1 knockout HeLa cell lysate (20μg)Lanes 1- 2: Merged signal (red and green). Green - ab40754 observed at 36 kDa. Red - loading control Anti-Vinculin antibody [VIN-54] ab130007 observed at 124 kDa.
ab40754 Recombinant Anti-Cyclin D1 antibody [EP272Y] was shown to specifically react with CCND1 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human CCND1 (Cyclin D1) knockout HeLa cell line ab255348 (knockout cell lysate ab263808) was used. Wild-type and CCND1 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab40754 and Anti-Vinculin antibody [VIN-54] were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
Lanes 1 - 2: Anti-Cyclin D1 antibody [EP272Y] - BSA and Azide free (ab227561) at 1/1000 dilution
Lanes 1 - 2: Western blot - Anti-Cyclin D1 antibody [EP272Y] (ab40754) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: CCND1 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 34 kDa
Observed band size: 36 kDa
Western blot - Human CCND1 (Cyclin D1) knockout HeLa cell lysate (ab263808)
Lane 1: Wild-type HeLa cell lysate (20µg)
Lane 2: CCND1 knockout HeLa cell lysate (20µg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-Cyclin D1 antibody [SP4] ab16663 observed at 36 kDa. Red - loading control Anti-Vinculin antibody [VIN-54] ab130007 observed at 124 kDa.
Anti-Cyclin D1 antibody [SP4] ab16663 Recombinant Anti-Cyclin D1 antibody [SP4] was shown to specifically react with CCND1 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human CCND1 (Cyclin D1) knockout HeLa cell line ab255348 (knockout cell lysate ab263808) was used. Wild-type and CCND1 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-Cyclin D1 antibody [SP4] ab16663 and Anti-Vinculin antibody [VIN-54] were incubated overnight at 4°C at 1 in 200 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-Cyclin D1 antibody [SP4] (Anti-Cyclin D1 antibody [SP4] ab16663) at 1/200 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: CCND1 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 34 kDa
Observed band size: 36 kDa
Sanger Sequencing - Human CCND1 (Cyclin D1) knockout HeLa cell lysate (ab263808)
Homozygous: 5 bp deletion in exon 1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com